Sulfur Hexafluoride

Phase 3Small molecule

Sulfur Hexafluoride is one of 17 small molecule programs targeting Rhegmatogenous Retinal Detachment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rhegmatogenous Retinal DetachmentActive, not recruiting

UltrasoundWithdrawn

Rhegmatogenous Retinal DetachmentPreclinical

Active, not recruiting

UltrasoundPhase 3

Withdrawn

Competition

Competitive Landscape

18 competitors in Ultrasound

#DrugCompanyPhaseTrials

Reglan

IIstituto Clinico Humanitas

Phase 3

1 2

Sonovue

BBracco Diagnostics, Inc

Phase 3

2 3

Tegretol

Novartis

Phase 1

1 4

Robitussin

Pfizer

Phase 1

1 5

Sulfur Hexafluoride

TTurku University Hospital

Phase 3

2 6

Ativan

BBausch Health Americas, Inc.

Phase 1

1 7

Nimotop

AAzurity Pharmaceuticals

Phase 1

1 8

Carbocaine

Pfizer

Preclinical

1 9

Marcaine

IInnocoll

Preclinical

4 10

Sulfur Hexafluoride Lipid Microspheres

Jjohn eisenbrey

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Recruiting

Ultrasound

NCT05648812

Clinical

Trials by Indication[1]

Ultrasound2 trials

Neonatal Brain Ultrasound With CEUS and Elastography

Recruiting·TTurku University Hospital·Phase 3·NCT05648812·100 enrolled

Preterm Neonates Brain Ultrasound With CEUS and Elastography

Withdrawn·TTurku University Hospital·Phase 3·NCT05694611

Rhegmatogenous Retinal Detachment1 trial

Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment

Unknown status·SSunnybrook Health Sciences Centre·N/A·NCT02185469·30 enrolled

Crohn's Disease1 trial

Ultrasound Evaluation of Crohn's Disease

Terminated·MMayo Clinic·Phase 4·NCT03235180·9 enrolled

Unspecified1 trial

The Silicone Study

Completed·NNational Eye Institute (NEI)·Phase 3·NCT00000140

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Sulfur Hexafluoride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sulfur Hexafluoride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sulfur Hexafluoride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Turku University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTurku University Hospital

Sulfur Hexafluoride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Ultrasound2 trials

Rhegmatogenous Retinal Detachment1 trial

Crohn's Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News